Vaxart Inc Stock Working Capital

VXRT Stock

USD 0.61 0.01 1.67%

Vaxart Inc fundamentals help investors to digest information that contributes to Vaxart's financial success or failures. It also enables traders to predict the movement of Vaxart Stock. The fundamental analysis module provides a way to measure Vaxart's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaxart stock.

	Last Reported	Projected for Next Year
Net Working Capital	31.8 M	30.2 M
Change In Working Capital	-10.8 M	-10.3 M

Net Working Capital is likely to drop to about 30.2 M in 2024. Change In Working Capital is likely to gain to about (10.3 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Vaxart Inc Company Working Capital Analysis

Vaxart's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Vaxart Working Capital

31.81 M

Most of Vaxart's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vaxart Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Vaxart Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Vaxart is extremely important. It helps to project a fair market value of Vaxart Stock properly, considering its historical fundamentals such as Working Capital. Since Vaxart's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vaxart's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vaxart's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock	Good Will	Short Term Investments	Current Deferred Revenue	Net Tangible Assets	Long Term Debt	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Property Plant Equipment	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	-0.64	-0.53	-0.1	0.65	0.85	0.27	0.09	0.04	-0.41	-0.04	0.35	-0.3	0.8	-0.23	0.53	-0.23	0.48	-0.03	0.48	-0.24	0.88	0.83	-0.48
Total Stockholder Equity	0.98		-0.73	-0.37	-0.01	0.48	0.91	0.11	0.07	0.12	-0.36	-0.03	0.37	-0.22	0.83	-0.25	0.43	-0.27	0.58	0.06	0.35	-0.25	0.87	0.89	-0.48
Net Debt	-0.64	-0.73		-0.13	-0.13	-0.14	-0.91	0.34	-0.01	-0.1	-0.13	0.3	-0.01	0.15	-0.55	0.22	0.02	0.17	-0.61	0.03	0.29	0.21	-0.48	-0.71	0.26
Retained Earnings	-0.53	-0.37	-0.13		0.4	-0.84	-0.15	-0.83	-0.01	0.25	0.44	-0.05	-0.2	0.43	-0.38	-0.04	-0.75	-0.06	0.2	0.11	-0.89	-0.03	-0.48	-0.19	0.34
Net Receivables	-0.1	-0.01	-0.13	0.4		-0.43	0.05	-0.34	-0.39	0.24	0.3	-0.28	-0.09	-0.01	-0.03	-0.25	-0.39	-0.61	0.38	0.38	-0.25	-0.24	-0.42	-0.27	0.08
Total Liab	0.65	0.48	-0.14	-0.84	-0.43		0.35	0.62	0.17	-0.28	-0.38	-0.11	0.21	-0.48	0.37	-0.07	0.63	0.04	-0.09	-0.38	0.66	-0.08	0.54	0.32	-0.25
Total Current Assets	0.85	0.91	-0.91	-0.15	0.05	0.35		-0.19	-0.05	0.14	-0.04	-0.18	0.36	-0.23	0.71	-0.19	0.19	-0.22	0.6	0.02	0.03	-0.19	0.69	0.84	-0.42
Short Term Debt	0.27	0.11	0.34	-0.83	-0.34	0.62	-0.19		0.11	-0.25	-0.49	0.26	-0.2	-0.17	0.3	-0.14	0.79	0.14	-0.34	-0.17	0.85	-0.14	0.31	0.0	-0.3
Intangible Assets	0.09	0.07	-0.01	-0.01	-0.39	0.17	-0.05	0.11		-0.27	-0.7	-0.11	-0.32	-0.11	0.06	-0.13	-0.04	0.01	-0.09	-0.13	-0.01	-0.14	0.34	0.24	0.35
Accounts Payable	0.04	0.12	-0.1	0.25	0.24	-0.28	0.14	-0.25	-0.27		0.04	0.15	0.3	-0.01	0.17	-0.17	-0.11	-0.34	0.42	-0.12	0.02	-0.17	0.0	0.12	-0.14
Common Stock	-0.41	-0.36	-0.13	0.44	0.3	-0.38	-0.04	-0.49	-0.7	0.04		-0.14	-0.05	0.2	-0.42	0.15	-0.37	0.28	-0.06	0.14	-0.6	0.16	-0.62	-0.39	-0.04
Good Will	-0.04	-0.03	0.3	-0.05	-0.28	-0.11	-0.18	0.26	-0.11	0.15	-0.14		0.19	0.75	0.33	-0.14	0.57	0.49	-0.03	-0.19	0.27	-0.14	0.25	0.22	-0.21
Short Term Investments	0.35	0.37	-0.01	-0.2	-0.09	0.21	0.36	-0.2	-0.32	0.3	-0.05	0.19		-0.08	0.21	0.18	0.11	-0.14	0.19	0.03	0.29	0.18	0.34	0.33	-0.31
Current Deferred Revenue	-0.3	-0.22	0.15	0.43	-0.01	-0.48	-0.23	-0.17	-0.11	-0.01	0.2	0.75	-0.08		0.0	-0.1	0.12	0.55	-0.13	0.06	-0.32	-0.1	-0.06	0.06	0.09
Net Tangible Assets	0.8	0.83	-0.55	-0.38	-0.03	0.37	0.71	0.3	0.06	0.17	-0.42	0.33	0.21	0.0		-0.47	0.66	-0.13	0.52	-0.07	0.46	-0.48	0.8	0.83	-0.44
Long Term Debt	-0.23	-0.25	0.22	-0.04	-0.25	-0.07	-0.19	-0.14	-0.13	-0.17	0.15	-0.14	0.18	-0.1	-0.47		-0.33	0.05	-0.17	-0.06	-0.09	1.0	-0.12	-0.22	-0.01
Capital Surpluse	0.53	0.43	0.02	-0.75	-0.39	0.63	0.19	0.79	-0.04	-0.11	-0.37	0.57	0.11	0.12	0.66	-0.33		0.36	-0.08	-0.18	0.77	-0.34	0.59	0.42	-0.43
Deferred Long Term Liab	-0.23	-0.27	0.17	-0.06	-0.61	0.04	-0.22	0.14	0.01	-0.34	0.28	0.49	-0.14	0.55	-0.13	0.05	0.36		-0.54	0.0	-0.12	0.05	0.0	0.0	0.01
Long Term Investments	0.48	0.58	-0.61	0.2	0.38	-0.09	0.6	-0.34	-0.09	0.42	-0.06	-0.03	0.19	-0.13	0.52	-0.17	-0.08	-0.54		-0.13	-0.07	-0.17	0.35	0.48	-0.15
Short Long Term Debt	-0.03	0.06	0.03	0.11	0.38	-0.38	0.02	-0.17	-0.13	-0.12	0.14	-0.19	0.03	0.06	-0.07	-0.06	-0.18	0.0	-0.13		-0.12	-0.07	-0.1	-0.04	0.0
Property Plant Equipment	0.48	0.35	0.29	-0.89	-0.25	0.66	0.03	0.85	-0.01	0.02	-0.6	0.27	0.29	-0.32	0.46	-0.09	0.77	-0.12	-0.07	-0.12		-0.1	0.49	0.18	-0.39
Long Term Debt Total	-0.24	-0.25	0.21	-0.03	-0.24	-0.08	-0.19	-0.14	-0.14	-0.17	0.16	-0.14	0.18	-0.1	-0.48	1.0	-0.34	0.05	-0.17	-0.07	-0.1		-0.12	-0.22	-0.01
Net Invested Capital	0.88	0.87	-0.48	-0.48	-0.42	0.54	0.69	0.31	0.34	0.0	-0.62	0.25	0.34	-0.06	0.8	-0.12	0.59	0.0	0.35	-0.1	0.49	-0.12		0.92	-0.42
Net Working Capital	0.83	0.89	-0.71	-0.19	-0.27	0.32	0.84	0.0	0.24	0.12	-0.39	0.22	0.33	0.06	0.83	-0.22	0.42	0.0	0.48	-0.04	0.18	-0.22	0.92		-0.41
Capital Stock	-0.48	-0.48	0.26	0.34	0.08	-0.25	-0.42	-0.3	0.35	-0.14	-0.04	-0.21	-0.31	0.09	-0.44	-0.01	-0.43	0.01	-0.15	0.0	-0.39	-0.01	-0.42	-0.41

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Vaxart

Working Capital Over Time

Vaxart Capital Surpluse

Capital Surpluse

528.88 Million

At this time, Vaxart's Capital Surpluse is comparatively stable compared to the past year.

As per the company's disclosures, Vaxart Inc has a Working Capital of 31.81 M. This is 92.53% lower than that of the Biotechnology sector and 94.09% lower than that of the Health Care industry. The working capital for all United States stocks is 97.85% higher than that of the company.

Vaxart Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaxart's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaxart could also be used in its relative valuation, which is a method of valuing Vaxart by comparing valuation metrics of similar companies.

Vaxart is currently under evaluation in working capital category among its peers.

Vaxart Current Valuation Drivers

We derive many important indicators used in calculating different scores of Vaxart from analyzing Vaxart's financial statements. These drivers represent accounts that assess Vaxart's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vaxart's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	7.5M	504.2M	761.5M	122.6M	83.0M	139.5M
Enterprise Value	(3.7M)	384.5M	630.8M	100.3M	74.7M	127.8M

Vaxart Fundamentals

	Return On Equity	-0.92
	Return On Asset	-0.4
	Operating Margin	(2.54) %
	Current Valuation	95.98 M
	Shares Outstanding	227.48 M
	Shares Owned By Insiders	0.87 %
	Shares Owned By Institutions	17.80 %
	Number Of Shares Shorted	11.27 M
	Price To Book	1.99 X
	Price To Sales	9.80 X
	Revenue	7.38 M
	Gross Profit	(80.95 M)
	EBITDA	(74.72 M)
	Net Income	(82.47 M)
	Cash And Equivalents	129.55 M
	Cash Per Share	1.02 X
	Total Debt	26.51 M
	Debt To Equity	0.09 %
	Current Ratio	8.65 X
	Book Value Per Share	0.38 X
	Cash Flow From Operations	(70.45 M)
	Short Ratio	11.71 X
	Earnings Per Share	(0.40) X
	Target Price	4.83
	Number Of Employees	109
	Beta	0.7
	Market Capitalization	136.49 M
	Total Asset	91.83 M
	Retained Earnings	(409.57 M)
	Working Capital	31.81 M
	Net Asset	91.83 M

About Vaxart Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vaxart Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxart using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxart Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC